Company Also Announces New Name: Quantum Cyber and Change in Nasdaq Ticker symbol
BERKELEY, Calif., March 11, 2026 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company focused on the early detection of cancer, has announced the appointment of Robert P. Liscouski as Chairman of its Board of Directors. Additionally, the Company revealed plans to change its name to Quantum Cyber and its Nasdaq ticker symbol to QUCY, effective March 12, 2026. The formal election of Mr. Liscouski and the company name change are scheduled to be finalized at the Company’s extraordinary general meeting planned for April 2026. The company will commence operations as Quantum Cyber and trade under the symbol QUCY starting March 12, 2026.
Mr. Liscouski is a recognized commentator on Homeland Security, Terrorism, and Cyber Security issues, frequently appearing on CNBC, CNN, BBC, Fox News, and other business and security media outlets. He has also testified before Congress on Homeland Security matters. Mr. Liscouski holds a Master of Public Administration from the John F. Kennedy School of Government at Harvard University.
Government Technology Initiatives
In 2003, following the 9/11 attacks, President George W. Bush appointed Mr. Liscouski as the inaugural Assistant Secretary for Infrastructure Protection upon the establishment of the U.S. Department of Homeland Security. In this role, he was responsible for the design, development, implementation, and management of the Office of Infrastructure Protection. This involved integrating various units from other government agencies, including the FBI, DoD, General Services Administration, the Department of Energy, and the Department of Commerce, and led to the creation of the National Cyber Security Division. Mr. Liscouski’s foundational work was instrumental in the establishment of the current Critical Infrastructure and Security Agency (CISA).
Cybersecurity and AI Innovations
Most recently, Mr. Liscouski served as co-founder, CEO, and Chairman of Quantum Computing Inc., an innovative integrated photonics company that produces accessible and affordable quantum machines. His technological leadership also extends to artificial intelligence and high-performance computing. As a co-founder of Fog Data Sciences, LLC, he played a key role in developing geo-location intelligence solutions that utilize AI and advanced computing capabilities. These solutions address critical needs within law enforcement and the U.S. Security and Intelligence Community by applying cutting-edge technology to complex security challenges. Earlier in his career, Mr. Liscouski was the Director of Information Assurance at The Coca-Cola Company, where he was responsible for evaluating, designing, and implementing the company’s Information Security Program.
The Company had previously indicated its intention to maintain its focus on developing its pancreatic cancer screening business in the U.S., while also exploring opportunities to divest its colorectal cancer screening assets and wind down its German subsidiary. Progress is being made across all these initiatives.
David Lazar, the current Chairman of the Board, stated, “Robert is a seasoned global executive, a proven technology leader and security expert with over 35 years of experience spanning both the public and private sectors which makes him a perfect fit for us. His career is marked by significant contributions to high tech initiatives, cybersecurity, and critical infrastructure protection, all of which fit perfectly into our long-term plans. Robert’s high-tech leadership includes co-founder, Chairman, and former CEO of Quantum Computing Inc. (Nasdaq: QUBT), in which he spearheaded the development of cutting-edge quantum computing technology. Under his leadership, the company became the first pure-play public company in the quantum computing market, focusing on nano photonic based hardware to help revolutionize the future of computing.”
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) in inability to successfully pursue our new initiatives; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025 and its mid-year report on Form 6-K filed on September 26, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
Investor Inquiries:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
